NIP
XENE icon

Nicholas Investment Partners’s Xenon Pharmaceuticals XENE Stock Holding History

Nicholas Investment Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.9M Buy
395,844
+148,743
+60% +$8.26M 1.35% 11
2026
Q1 		$14.4M Buy
247,101
+4,112
+2% +$189K 1.04% 25
2025
Q4 		$10.9M Buy
242,989
+123,891
+104% +$5.2M 0.79% 41
2025
Q3 		$4.78M Buy
119,098
+50,202
+73% +$1.77M 0.37% 103
2025
Q2 		$2.16M Sell
68,896
-18,072
-21% -$589K 0.19% 150
2025
Q1 		$2.92M Buy
86,968
+72,310
+493% +$2.75M 0.3% 117
2024
Q4 		$575K Hold
14,658
– – 0.05% 204
2024
Q3 		$577K Buy
+14,658
New +$591K 0.05% 202
2024
Q2 		– Sell
-167,926
Closed -$7.23M – 242
2024
Q1 		$7.23M Buy
167,926
+80,174
+91% +$3.69M 0.74% 41
2023
Q4 		$4.04M Sell
87,752
-766,695
-90% -$27.1M 0.47% 77
2023
Q3 		$29.2M Buy
854,447
+63,329
+8% +$2.37M 2.18% 9
2023
Q2 		$30.5M Buy
791,118
+354,403
+81% +$14.1M 2.08% 12
2023
Q1 		$15.6M Buy
436,715
+184,413
+73% +$6.81M 1.19% 30
2022
Q4 		$9.95M Buy
+252,302
New +$9.19M 0.87% 45

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Nicholas Investment Partners's XENE Position: Q2 2026 in Review

Nicholas Investment Partners increased its Xenon Pharmaceuticals (XENE) stake by 60% in Q2 2026, buying an estimated $8.26M and bringing the position to 395,844 shares worth $23.9M. The position accounts for 1.35% of the portfolio, ranked #11.

Nicholas Investment Partners first reported a position in XENE in Q4 2022 and has held it in 14 quarters since. The position peaked at $30.5M in Q2 2023. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Nicholas Investment Partners held 395,844 shares of Xenon Pharmaceuticals worth $23.9M as of Q2 2026.
  • Nicholas Investment Partners bought 148,743 Xenon Pharmaceuticals shares in Q2 2026, an estimated $8.26M.
  • Xenon Pharmaceuticals made up 1.35% of Nicholas Investment Partners's portfolio in Q2 2026, its #11 holding.
  • Nicholas Investment Partners first reported a position in Xenon Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • Nicholas Investment Partners's Xenon Pharmaceuticals position peaked at $30.5M in Q2 2023.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.